Syndax gets TIME recognition as Wainwright keeps USD 38 target for Syndax Pharmaceuticals stock

Published on 10/18/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Syndax's Revuforj entered TIME's 2026 list on October 15, 2026. A USD 38.00 target stayed in place for Syndax Pharmaceuticals stock.

Pipeline and catalysts after October

Revuforj entered TIME's 2026 inventions list on October 15, 2026.
MAXPIRe tested axatilimab in a 145-patient Phase 2 trial across 62 sites on October 12, 2026.
H.C. Wainwright kept its USD 38.00 target on October 13, 2026, while Q3 results are scheduled for November 2, 2026.

SNDX, US87164F1057, Illustration mit AI erstellt.

Syndax Pharmaceuticals (ISIN US87164F1057) said on October 15, 2026 that Revuforj, its revumenib treatment, had been selected for TIME's Best Inventions of 2026 list. According to GlobeNewswire, the annual selection covered 300 inventions across several categories, with Revuforj included in Medical and Healthcare.

Recognition meets a mixed pipeline

The recognition gives Syndax's commercial portfolio a positive visibility point after a setback in development. On October 12, 2026, the company said its MAXPIRe Phase 2 trial of axatilimab in idiopathic pulmonary fibrosis did not meet its primary endpoint.

As Syndax Pharmaceuticals reported, MAXPIRe was a 145-patient, 26-week study conducted across 62 sites in 14 countries. The company ended further development in idiopathic pulmonary fibrosis, while continuing axatilimab programs in chronic graft-versus-host disease.

What does the trial miss mean?

The immediate implication is a narrower development path for axatilimab, not a halt to the broader program. Syndax said safety and tolerability were comparable to placebo, no new safety signals appeared, and no treatment-related fatal adverse events occurred in either trial arm.

The company also retains two approved medicines in its commercial-stage portfolio. Revuforj is an FDA-approved menin inhibitor, while Niktimvo is an FDA-approved antibody for chronic graft-versus-host disease, according to the October 12 release.

Two dates shape the next readout

On October 13, 2026, H.C. Wainwright reiterated a Buy rating and kept its USD 38.00 price target after the MAXPIRe result, as reported by Markets Insider.

The next scheduled reporting date is November 2, 2026, when Syndax is estimated to publish third-quarter results after the market close, with a conference call at 4:30 p.m. ET, according to MarketBeat.

Commercial execution remains central

For Syndax Pharmaceuticals stock, the next evidence will come from the commercial performance of Revuforj and Niktimvo and from the remaining axatilimab trials. The October events leave investors weighing a recognized lead product against a discontinued Phase 2 indication and several later-stage clinical milestones.

The further course of trading is shown by the continuously updated real-time quote of Syndax Pharmaceuticals stock.